Literature DB >> 10484476

20-HETE and the kidney: resolution of old problems and new beginnings.

J C McGiff1, J Quilley.   

Abstract

The protean properties of 20-hydroxyeicosatetraenoic acid (HETE), vasoactivity, mitogenicity, and modulation of transport in key nephron segments, serve as the basis for the essential roles of 20-HETE in the regulation of the renal circulation and electrolyte excretion and as a second messenger for endothelin-1 and mediator of selective renal effects of ANG II. Renal autoregulation and tubular glomerular feedback are mediated by 20-HETE through constriction of preglomerular arterioles, responses that are maintained by 20-HETE inhibition of calcium-activated potassium channels. 20-HETE modulates ion transport in the proximal tubules and the thick ascending limb by affecting the activities of Na+-K+-ATPase and the Na+-K+-2Cl- cotransporter, respectively. The range and diversity of activity of 20-HETE derives in large measure from COX-dependent transformation of 20-HETE to products affecting vasomotion and salt and water excretion. Nitric oxide (NO) exerts a negative modulatory effect on 20-HETE formation; inhibition of NO synthesis produces marked perturbation of renal function resulting from increased 20-HETE production. 20-HETE is an essential component of interactions involving several hormonal systems that have central roles in blood pressure homeostasis, including angiotensins, endothelins, NO, and cytokines. 20-HETE is the preeminent renal eicosanoid, overshadowing PGE2 and PGI2. This review is intended to provide evidence for the physiological roles for cytochrome P-450-derived eicosanoids, particularly 20-HETE, and seeks to extend this knowledge to a conceptual framework for overall cardiovascular function.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10484476     DOI: 10.1152/ajpregu.1999.277.3.R607

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  41 in total

Review 1.  A new class of lipid mediators: cytochrome P450 arachidonate metabolites.

Authors:  M A Carroll; J C McGiff
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 2.  Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.

Authors:  Hong C Shen; Bruce D Hammock
Journal:  J Med Chem       Date:  2012-01-17       Impact factor: 7.446

3.  Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation.

Authors:  Dominik N Muller; Cosima Schmidt; Eduardo Barbosa-Sicard; Maren Wellner; Volkmar Gross; Hantz Hercule; Marija Markovic; Horst Honeck; Friedrich C Luft; Wolf-Hagen Schunck
Journal:  Biochem J       Date:  2007-04-01       Impact factor: 3.857

4.  Contribution of 20-HETE to augmented myogenic constriction in coronary arteries of endothelial NO synthase knockout mice.

Authors:  An Huang; Dong Sun; Changdong Yan; John R Falck; Gabor Kaley
Journal:  Hypertension       Date:  2005-07-25       Impact factor: 10.190

5.  Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension.

Authors:  V R Holla; F Adas; J D Imig; X Zhao; E Price; N Olsen; W J Kovacs; M A Magnuson; D S Keeney; M D Breyer; J R Falck; M R Waterman; J H Capdevila
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

Review 6.  Conflicting roles of 20-HETE in hypertension and renal end organ damage.

Authors:  Chao Zhang; George W Booz; Qing Yu; Xiaochen He; Shaoxun Wang; Fan Fan
Journal:  Eur J Pharmacol       Date:  2018-06-07       Impact factor: 4.432

7.  Role of CYP epoxygenases in A2A AR-mediated relaxation using A2A AR-null and wild-type mice.

Authors:  Mohammed A Nayeem; Samuel M Poloyac; John R Falck; Darryl C Zeldin; Catherine Ledent; Dovenia S Ponnoth; Habib R Ansari; S Jamal Mustafa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-09-19       Impact factor: 4.733

Review 8.  Cytochrome P450 and Lipoxygenase Metabolites on Renal Function.

Authors:  John D Imig; Md Abdul Hye Khan
Journal:  Compr Physiol       Date:  2015-12-15       Impact factor: 9.090

9.  Expression of CYP4F2 in human liver and kidney: assessment using targeted peptide antibodies.

Authors:  Vandana Hirani; Anton Yarovoy; Anita Kozeska; Ronald P Magnusson; Jerome M Lasker
Journal:  Arch Biochem Biophys       Date:  2008-07-16       Impact factor: 4.013

10.  Association of a CYP4A11 variant and blood pressure in black men.

Authors:  James V Gainer; Michael S Lipkowitz; Chang Yu; Michael R Waterman; Elliott P Dawson; Jorge H Capdevila; Nancy J Brown
Journal:  J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.